The recently released FY 2026 National Defense Authorization Act (NDAA) marks a watershed moment in the integration of biotechnology as a core element in the current and near future development of United States (U.S.) defense policy and military capability. The legislation’s 17 new biotechnology provisions, which span research, strategy, supply chains, ethics, and intelligence integration, reflect bipartisan recognition that emerging biotechnologies have now become foundational to the character and conduct of future conflict. For the Joint Force, understanding the tactical, operational, strategic and ethical ramifications of these changes is imperative. Read More.